Eikon Therapeutics

What Eikon Therapeutics does

Eikon Therapeutics is a late-stage clinical biopharmaceutical company that develops live-cell resolution microscopy and engineering tools for drug discovery. Founded in 2019 in Millbrae, California by Robert Tjian, Luke Lavis, Xavier Darzacq, and Nobel laureate Eric Betzig, the company completed an upsized initial public offering on Nasdaq (ticker: EIKN) on February 5, 2026, raising approximately $381 million in gross proceeds. Eikon applies its proprietary Single Molecule Tracking (SMT) platform — built on Nobel Prize-winning super-resolution microscopy and extended through the proprietary Oblique Line Scan (OLS) illumination technology — to visualize and measure the real-time movement of individual proteins in living cells at industrial scale, generating approximately one petabyte of imaging data per week.

The company's pipeline centers on clinical-stage oncology candidates, including EIK1001, a TLR7/8 dual agonist in Phase 2 development in first-line Stage 4 NSCLC and advanced melanoma in combination with pembrolizumab; EIK1003 and EIK1004, PARP1-selective inhibitors in Phase 1/2 development (EIK1004 is differentiated by CNS penetrance); EIK1005, a WRN helicase inhibitor that entered Phase 1/2 in February 2026 as the first program advanced from internal SMT discovery; and EIK1006, an androgen receptor antagonist in IND-enabling studies. The Eikon Systems business unit, established in 2024, extends SMT imaging instruments to external academic and industry researchers through the Eikon Technology Access Program.

Eikon is pre-revenue and operates a capital-intensive, clinical-development-driven business model with no approved products on market. Revenue mechanics currently consist of (1) capital deployment (over $1.1 billion raised privately plus $381M IPO proceeds) funding registration-enabling Phase 2/3 trials and Phase 1 programs across 28 countries on 5 continents, and (2) early-stage Eikon Systems instrument access. The company reported a FY2025 net loss of $333.6M and Q1 2026 net loss of $83.0M, with cash, cash equivalents, and marketable securities of $596.0 million as of March 31, 2026, expected to fund operations into the second half of 2027. Strategic collaboration with Merck & Co. covers pembrolizumab supply for EIK1001 trials, and Impact Therapeutics handles greater China clinical operations for EIK1003/EIK1004.

Name

Eikon Therapeutics

Legal name

Eikon Therapeutics, Inc.

Website

http://www.eikontx.com

Company type

Public

Founded year

2019

Operating status

Ipo

Headcount range

251–500 employees

Short description

Eikon Therapeutics is a clinical-stage biopharmaceutical company that uses proprietary live-cell Single Molecule Tracking microscopy — built on Nobel Prize-winning super-resolution optics — to discover and develop oncology drug candidates including TLR7/8 and PARP1 inhibitors, serving patients with advanced and treatment-resistant cancers.

Ownership category

akta.pro rank

Product category

Clinical-stage Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Oncology therapeutics
• Single molecule imaging
• Live-cell microscopy
• Clinical-stage biopharmaceuticals
• Drug discovery platform

Headquarters

HQ city

Hayward

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

1. Pre-revenue clinical-stage biopharmaceutical: Eikon is pre-revenue as of Q1 2026; net loss was $83.0 million in Q1 2026 and $333.6 million for full-year 2025, with no approved products on the market. Future revenue expected from commercialization of oncology drug candidates (EIK1001, EIK1003, EIK1004, EIK1005, EIK1006) once approved.
2. Eikon Systems / Technology Access Program: Eikon Systems business unit extends state-of-the-art imaging instruments (SMT platform) to select academic and industry researchers through the Eikon Technology Access Program, enabling study of model systems using Eikon's instruments; an instrument/access-based revenue stream parallel to therapeutic development.

Pricing tiers

Go-to-market motion4 records

Distribution channels2 records

Marketing channels9 records

Core offering

Eikon Therapeutics is a late-stage clinical biopharmaceutical company that discovers and develops oncology drug candidates using its proprietary Single Molecule Tracking (SMT) platform, which combines Nobel Prize-winning super-resolution microscopy, bespoke high-throughput automation, and AI/ML-driven data analytics to visualize and measure the real-time movement of individual proteins in living cells. Its pipeline includes clinical-stage candidates EIK1001 (TLR7/8 dual agonist), EIK1003 and EIK1004 (PARP1-selective inhibitors), and EIK1005 (WRN helicase inhibitor), with an IND-enabling AR antagonist EIK1006, alongside an Eikon Systems unit that provides external researchers access to its imaging instruments.

Product overview

Eikon Therapeutics is a late-stage clinical biopharmaceutical company built around a unified proprietary platform-plus-pipeline architecture. The foundation is the Single Molecule Tracking (SMT) Platform, a core discovery engine that integrates Nobel Prize-winning super-resolution microscopy (including the Oblique Line Scan/OLS illumination technology), bespoke high-throughput automation, and AI/ML-driven data analytics to visualize and measure the real-time movement of individual proteins in living cells at industrial scale. This platform feeds directly into a portfolio of clinical-stage oncology drug candidates — EIK1001 (TLR7/8 dual agonist in Phase 2 for NSCLC and melanoma), EIK1003 and EIK1004 (PARP1-selective inhibitors in Phase 1, including the CNS-penetrant EIK1004), and EIK1005 (WRN helicase inhibitor in Phase 1) — together with earlier-stage assets such as EIK1006 (androgen receptor antagonist in IND-enabling studies) and undisclosed neuroscience programs. The SMT platform also powers the Eikon Systems business unit, which extends the imaging technology to external academic and industry researchers through the Technology Access Program, creating a discovery engine that drives both internal pipeline advancement and external scientific collaboration.

Differentiator

Problem solved

Functional benefit

Brands

• Eikon Systems: Business unit that provides academic and industry researchers access to Eikon's proprietary imaging instruments and Single Molecule Tracking (SMT) technology through the Eikon Technology Access Program, enabling the study of protein motion in living cells.

Products and services

• Single Molecule Tracking (SMT) Platform Eikon's proprietary core discovery engine that visualizes and measures the real-time movement of individual proteins in living cells. Captures hundreds of thousands of protein motion events in less than a second and produces high-dimensional datasets describing protein state, localization, diffusion rates, angular movement, processivity, and rate constants. Used internally for drug target identification and SAR optimization, and accessed externally by researchers through the Eikon Systems Technology Access Program.
• EIK1001 Investigational systemically administered dual-agonist of Toll-like receptors 7 and 8 (TLR7/8) designed to stimulate both innate and adaptive immune responses and complement PD-(L)1 blockade. In Phase 2/3 development in advanced melanoma (TeLuRide-006) and first-line Stage 4 non-small cell lung cancer (TeLuRide-005, TeLuRide-008) in combination with pembrolizumab with or without chemotherapy. Designed for outpatient systemic administration.
• EIK1003 Next-generation, highly-selective PARP1 inhibitor designed to leave PARP2 signaling intact, potentially reducing hematological toxicity associated with first-generation non-selective PARP inhibitors. In Phase 1/2 trial (EIK1003-001) as monotherapy and in combination with hormonal blockade (prostate cancer) or chemotherapy (breast or ovarian cancer).
• EIK1004 CNS-penetrant, highly-selective PARP1 inhibitor differentiated by its ability to cross the blood-brain barrier. In Phase 1/2 trial (EIK1004-001) in patients with advanced solid tumors, including those with brain metastases. In-licensed from Impact Therapeutics.
• EIK1005 WRN (Werner) helicase inhibitor with demonstrated in vitro activity in MSI-high cancer cells. Internally derived and optimized using Eikon's SMT technology platform. In Phase 1/2 trial in patients with advanced solid tumors including MSI-H or dMMR tumors, both as monotherapy and in combination with pembrolizumab.
• EIK1006

Quantifiable outcome

• EIK1001 Phase 2 in first-line Stage 4 NSCLC: 63.1% objective response rate (ORR) and 90.8% disease control rate (DCR) across 65 evaluable patients in combination with pembrolizumab and chemotherapy; squamous cohort 72.4% ORR, non-squamous cohort 55.6% ORR.
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• Merck & Co. (MSD)flagshipStrategic or Co-development Partner · 1 May 2025Clinical trial collaboration and supply agreement: Merck supplies pembrolizumab (Keytruda) for Eikon's TeLuRide-006 Phase 2/3 trial of EIK1001 in advanced melanoma (first patient enrolled May 2025). Eikon is the sponsor of the trial. Merck is also expected to purchase approximately 10% of Eikon's IPO offering shares (Feb 2026). Merck further deepened oncology engagement with Eikon as a key collaborator.
• Impact Therapeutics (Shanghai) Inc.coreStrategic or Co-development Partner · 1 June 2023Collaboration partner for EIK1003 and EIK1004 PARP1-selective inhibitor programs. Impact Therapeutics is responsible for trial oversight in greater China; Eikon leads global development. A $5.0 million milestone payment to Impact Therapeutics was made in Q1 2026 for advancement of EIK1003 into Phase 2 development. Co-developed IND-enabling studies for brain-penetrant PARP1 candidate IMP17307 (now EIK1004).

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eikon-therapeutics-inc
• Xx.com/eikontx

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eikon Therapeutics